

# Jordi A MatÃ- as-Guiu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/248773/publications.pdf>

Version: 2024-02-01

164  
papers

2,944  
citations

172207

29  
h-index

253896

43  
g-index

179  
all docs

179  
docs citations

179  
times ranked

3971  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and Verbal Fluency in Alzheimer’s Disease and Frontotemporal Dementia: Clinical and Metabolic Correlates. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 947-962.	1.2	10
2	The Five-Point Test: Normative data for middle-aged and elderly Spaniards. <i>Applied Neuropsychology Adult</i> , 2022, 29, 1323-1331.	0.7	2
3	Identification of the main components of spontaneous speech in primary progressive aphasia and their neural underpinnings using multimodal MRI and FDG-PET imaging. <i>Cortex</i> , 2022, 146, 141-160.	1.1	9
4	Speech pause distribution as an early marker for Alzheimer’s disease. <i>Speech Communication</i> , 2022, 136, 107-117.	1.6	16
5	Diagnosis of Alzheimer’s disease and behavioural variant frontotemporal dementia with machine learning-aided neuropsychological assessment using feature engineering and genetic algorithms. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	16
6	Examining Association of Personality Characteristics and Neuropsychiatric Symptoms in Post-COVID Syndrome. <i>Brain Sciences</i> , 2022, 12, 265.	1.1	6
7	The effects of the COVID-19 pandemic on neuropsychiatric symptoms in dementia and carer mental health: an international multicentre study. <i>Scientific Reports</i> , 2022, 12, 2418.	1.6	24
8	Body Complexion and Circulating Lipids in the Risk of TDP-43 Related Disorders. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 838141.	1.7	5
9	The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination. <i>Life</i> , 2022, 12, 474.	1.1	6
10	Editorial: COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanisms of Infection and New Tools for the Therapeutic Approach. <i>Frontiers in Neurology</i> , 2022, 13, 838227.	1.1	1
11	Cognitive dysfunction associated with COVID-19: A comprehensive neuropsychological study. <i>Journal of Psychiatric Research</i> , 2022, 150, 40-46.	1.5	76
12	Persistent olfactory dysfunction after COVID-19 is associated with reduced perfusion in the frontal lobe. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 194-198.	1.0	26
13	Advances in Primary Progressive Aphasia. <i>Brain Sciences</i> , 2022, 12, 636.	1.1	0
14	Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders. <i>Biomedicines</i> , 2022, 10, 1105.	1.4	13
15	Validation of two new scales for the assessment of fatigue in Multiple Sclerosis: F-2-MS and FACIT-F. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103826.	0.9	4
16	Neuropsychological Predictors of Fatigue in Post-COVID Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 3886.	1.0	7
17	GA-MADRID: design and validation of a machine learning tool for the diagnosis of Alzheimer’s disease and frontotemporal dementia using genetic algorithms. <i>Medical and Biological Engineering and Computing</i> , 2022, 60, 2737-2756.	1.6	12
18	Development, Spanish Normative Data, and Validation of a Social Cognition Battery in Prodromal Alzheimer’s Disease and Multiple Sclerosis. <i>Archives of Clinical Neuropsychology</i> , 2021, 36, 711-722.	0.3	5

#	ARTICLE	IF	CITATIONS
19	Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal. Journal of Medical Virology, 2021, 93, 546-549.	2.5	32
20	<i>ACE2, TMPRSS2</i>, and Furin variants and SARS-CoVâ€2 infection in Madrid, Spain. Journal of Medical Virology, 2021, 93, 863-869.	2.5	72
21	Whole-Exome Sequencing and C9orf72 Analysis in Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 80, 985-990.	1.2	3
22	Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System. International Journal of Molecular Sciences, 2021, 22, 5192.	1.8	4
23	Validation technique and improvements introduced in a new dedicated brain positron emission tomograph (CareMiBrain). Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 239-248.	0.1	1
24	Underpinnings of verbal fluency in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103056.	0.9	1
25	Personalized Repetitive Transcranial Magnetic Stimulation for Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 84, 151-167.	1.2	17
26	Spanish Version of the Mini-Linguistic State Examination for the Diagnosis of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2021, 83, 771-778.	1.2	6
27	Reduced Blood RGS2 Expression in Mild Cognitive Impairment Patients. Frontiers in Aging Neuroscience, 2021, 13, 738244.	1.7	2
28	Application of Machine Learning to Electroencephalography for the Diagnosis of Primary Progressive Aphasia: A Pilot Study. Brain Sciences, 2021, 11, 1262.	1.1	8
29	Intranasal Administration of Undifferentiated Oligodendrocyte Lineage Cells as a Potential Approach to Deliver Oligodendrocyte Precursor Cells into Brain. International Journal of Molecular Sciences, 2021, 22, 10738.	1.8	6
30	â€œBrain Fogâ€•by COVID-19 or Alzheimerâ€™s Disease? A Case Report. Frontiers in Psychology, 2021, 12, 7240201		19
31	Editorial: Consequences of the COVID-19 Pandemic on Care for Neurological Conditions. Frontiers in Neurology, 2021, 12, 788912.	1.1	1
32	Genetic Algorithms for Optimized Diagnosis of Alzheimerâ€™s Disease and Frontotemporal Dementia Using Fluorodeoxyglucose Positron Emission Tomography Imaging. Frontiers in Aging Neuroscience, 2021, 13, 708932.	1.7	4
33	Machine learning for neuropsychological assessment of Alzheimerâ€™s disease and behavioral variant frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
34	Diagnosis of Alzheimerâ€™s disease and frontotemporal dementia using FDGâ€PET: Application of genetic algorithms. Alzheimer's and Dementia, 2021, 17, .	0.4	2
35	CoexpresiÃ³n de NG2/GFAP tras la diferenciaciÃ³n en cÃ©lulas transfectadas con las mutaciones de GFAP y en cÃ©lulas procedentes de gliomas indiferenciados. NeurologÃa, 2020, 35, 479-485.	0.3	0
36	Modelos experimentales de desmielinizaciÃ³n-remielinizaciÃ³n. NeurologÃa, 2020, 35, 32-39.	0.3	31

#	ARTICLE	IF	CITATIONS
37	Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101926.	0.9	16
38	Vitamin D increases remyelination by promoting oligodendrocyte lineage differentiation. <i>Brain and Behavior</i> , 2020, 10, e01498.	1.0	40
39	Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. <i>Frontiers in Immunology</i> , 2020, 11, 2163.	2.2	27
40	Death Rate Due to COVID-19 in Alzheimer's Disease and Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 537-541.	1.2	41
41	Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals. <i>Headache</i> , 2020, 60, 1697-1704.	1.8	57
42	Reading prosody in the non-fluent and logopenic variants of primary progressive aphasia. <i>Cortex</i> , 2020, 132, 63-78.	1.1	12
43	Variants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 1178-1184.	1.9	4
44	Posterior Cingulate Cortex Hypometabolism in Non-Amnesic Variants of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1569-1577.	1.2	7
45	Non-Convulsive Status Epilepticus in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 985-991.	1.2	1
46	Validation of the Spanish version of the Mini-Linguistic State Examination for the diagnosis of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2020, 16, e042817.	0.4	0
47	Metabolic correlates of neuropsychological assessment in behavioral variant frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e044097.	0.4	0
48	Personalized repetitive transcranial magnetic stimulation for non-fluent and semantic variants of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2020, 16, e047658.	0.4	0
49	Is the brain a reservoir organ for SARS-CoV2?. <i>Journal of Medical Virology</i> , 2020, 92, 2354-2355.	2.5	28
50	Memory Impairment in Relapsing-Remitting Multiple Sclerosis Using a Challenging Semantic Interference Task. <i>Frontiers in Neurology</i> , 2020, 11, 309.	1.1	5
51	Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102185.	0.9	118
52	Should We Adapt the Prescription Criteria for Specific Treatments for Migraine Due to the COVID-19 Pandemic?. <i>Headache</i> , 2020, 60, 1448-1449.	1.8	4
53	SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases. <i>Movement Disorders</i> , 2020, 35, 1104-1105.	2.2	16
54	An Online Observational Study of Patients With Olfactory and Gustatory Alterations Secondary to SARS-CoV-2 Infection. <i>Frontiers in Public Health</i> , 2020, 8, 243.	1.3	27

#	ARTICLE	IF	CITATIONS
55	Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102297.	0.9	25
56	Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 638.	1.1	11
57	Amyloid $\beta$ -Positron Emission Tomography in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damage. <i>Annals of Neurology</i> , 2020, 87, 988-988.	2.8	2
58	¿Va a cambiar la neurología tras la pandemia de COVID-19 en los próximos 5 años? Estudio de enfoque mediante informadores clave. <i>Neurología</i> , 2020, 35, 252-257.	0.3	13
59	Validation of the Neuronorma battery for neuropsychological assessment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102070.	0.9	12
60	¿Es esperable que haya cuadros neurológicos por la pandemia por SARS-CoV-2?. <i>Neurología</i> , 2020, 35, 170-175.	0.3	104
61	La gestión de la asistencia neurológica en tiempos de la pandemia de Covid-19. <i>Neurología</i> , 2020, 35, 233-237.	0.3	47
62	Cognitive Processes Underlying Verbal Fluency in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 629183.	1.1	17
63	Addenbrooke's Cognitive Examination. , 2020, , 379-393.		1
64	Inhibition impairment in frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer's disease: clinical assessment and metabolic correlates. <i>Brain Imaging and Behavior</i> , 2019, 13, 651-659.	1.1	26
65	A cognitive stress test for prodromal Alzheimer's disease: Multiethnic generalizability. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 550-559.	1.2	16
66	Differences in age of diagnosis in familial multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 91.	0.9	1
67	An application of machine learning with feature selection to improve diagnosis and classification of neurodegenerative disorders. <i>BMC Bioinformatics</i> , 2019, 20, 491.	1.2	37
68	Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 773-782.	1.2	10
69	Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer's Disease: Clinical and FDG-PET Correlation. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1263-1269.	1.2	15
70	Repetitive transcranial magnetic stimulation in a case of atypical parkinsonism. <i>Brain Stimulation</i> , 2019, 12, 1343-1344.	0.7	0
71	Machine learning in the clinical and language characterisation of primary progressive aphasia variants. <i>Cortex</i> , 2019, 119, 312-323.	1.1	31
72	Notch Signalling in the Hippocampus of Patients With Motor Neuron Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 302.	1.4	16

#	ARTICLE	IF	CITATIONS
73	Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using whole-exome next generation sequencing. <i>Brain and Behavior</i> , 2019, 9, e01272.	1.0	23
74	What is the meaning of PASAT rejection in multiple sclerosis?. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 559-562.	1.0	9
75	Clinical or neuroimaging profiles in the assessment of genetic variants associated with neurodegenerative diseases. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 419-421.	1.9	3
76	Diagnosis of Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Spectrum. , 2019, , 133-141.		0
77	Microcirculatory dysfunction in the heart and the brain. <i>Minerva Cardioangiologica</i> , 2019, 67, 318-329.	1.2	10
78	Vitamin D and remyelination in multiple sclerosis. <i>Neurología (English Edition)</i> , 2018, 33, 177-186.	0.2	12
79	Familial multiple sclerosis and association with other autoimmune diseases. <i>Brain and Behavior</i> , 2018, 8, e00899.	1.0	11
80	Vitamina D y remielinización en la esclerosis múltiple. <i>Neurología</i> , 2018, 33, 177-186.	0.3	26
81	La infusión intracerebroventricular prolongada de líquido cefalorraquídeo procedente de pacientes con esclerosis lateral amiotrófica provoca cambios histológicos en el cerebro y la médula espinal de la rata similares a los hallados en la enfermedad. <i>Neurología</i> , 2018, 33, 211-223.	0.3	25
82	Different apathy clinical profile and neural correlates in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 141-150.	1.3	33
83	La alteración de la mielina en la enfermedad de Alexander. <i>Neurología</i> , 2018, 33, 526-533.	0.3	6
84	Addenbrooke's Cognitive Examination III: un test neuropsicológico útil para el cribado y la obtención de perfiles cognitivos. <i>Neurología</i> , 2018, 33, 140.	0.3	7
85	Conversion between Addenbrooke's Cognitive Examination III and Mini-Mental State Examination. <i>International Psychogeriatrics</i> , 2018, 30, 1227-1233.	0.6	17
86	Identification of Cortical and Subcortical Correlates of Cognitive Performance in Multiple Sclerosis Using Voxel-Based Morphometry. <i>Frontiers in Neurology</i> , 2018, 9, 920.	1.1	31
87	Structural MRI correlates of PASAT performance in multiple sclerosis. <i>BMC Neurology</i> , 2018, 18, 214.	0.8	20
88	Prevalence of amyloid $\beta$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
89	Evaluation of the Safety and Efficacy of the Therapeutic Potential of Adipose-Derived Stem Cells Injected in the Cerebral Ischemic Penumbra. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2453-2465.	0.7	8
90	Histological changes in the rat brain and spinal cord following prolonged intracerebroventricular infusion of cerebrospinal fluid from amyotrophic lateral sclerosis patients are similar to those caused by the disease. <i>Neurología (English Edition)</i> , 2018, 33, 211-223.	0.2	2

#	ARTICLE	IF	CITATIONS
91	Clustering Analysis of FDG-PET Imaging in Primary Progressive Aphasia. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 230.	1.7	22
92	Novedades en esclerosis múltiple: la remielinización como objetivo terapéutico. <i>Medicina Clínica</i> , 2017, 148, 377-380.	0.3	7
93	Cerebrospinal fluid cytotoxicity does not affect survival in amyotrophic lateral sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 212-216.	1.0	7
94	Neural Basis of Cognitive Assessment in Alzheimer Disease, Amnesic Mild Cognitive Impairment, and Subjective Memory Complaints. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 730-740.	0.6	24
95	Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. <i>Brain and Behavior</i> , 2017, 7, e00671.	1.0	32
96	Amyloid PET in pseudotumoral multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 15-17.	0.9	7
97	Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology. <i>Prion</i> , 2017, 11, 205-213.	0.9	16
98	News in multiple sclerosis: Remyelination as a therapeutic target. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 377-380.	0.1	5
99	Reading difficulties in primary progressive aphasia in a regular language-speaking cohort of patients. <i>Neuropsychologia</i> , 2017, 101, 132-140.	0.7	18
100	FDG-PET/CT or MRI for the Diagnosis of Primary Progressive Aphasia?. <i>American Journal of Neuroradiology</i> , 2017, 38, E63-E63.	1.2	8
101	Comparative Diagnostic Accuracy of the ACE-III, MIS, MMSE, MoCA, and RUDAS for Screening of Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 43, 237-246.	0.7	80
102	Teaching Neuro Images : Adult-onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome). <i>Neurology</i> , 2017, 88, e113-e114.	1.5	3
103	Episodic Memory Dysfunction in Behavioral Variant Frontotemporal Dementia: A Clinical And FDG-PET Study. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1251-1264.	1.2	38
104	Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 733-742.	1.2	31
105	Addenbrooke's cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests. <i>International Psychogeriatrics</i> , 2017, 29, 105-113.	0.6	67
106	Inhibition of neurogenesis in a case of Marburg variant multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 71-76.	0.9	8
107	Comparison between FCSRT and LASSI-L to Detect Early Stage Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 103-111.	1.2	27
108	Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation. <i>Frontiers in Neurology</i> , 2017, 8, 643.	1.1	40

#	ARTICLE	IF	CITATIONS
109	Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis and sample size. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 79-79.	1.0	0
110	Análisis de las interconsultas al neurólogo de guardia por crisis comicial en un servicio de urgencias. <i>Neurología</i> , 2016, 31, 572-574.	0.3	3
111	Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging. <i>Frontiers in Neurology</i> , 2016, 7, 53.	1.1	44
112	Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. <i>Frontiers in Neurology</i> , 2016, 7, 195.	1.1	25
113	Pittsburgh compound B and other amyloid positron emission tomography tracers for the study of white matter and multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 166-166.	2.8	7
114	18F-FDG PET/TC y RM funcional en un caso de afasia progresiva primaria logopédica cruzada. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 394-397.	0.0	3
115	Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 243-250.	0.7	35
116	Analysis of the Relationship between the Month of Birth and Risk of Multiple Sclerosis in a Spanish Population. <i>European Neurology</i> , 2016, 76, 202-209.	0.6	9
117	Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2050-2060.	3.3	48
118	The Hayling Test: Development and Normalization of the Spanish Version. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 411-419.	0.3	25
119	Mielinólisis pontina y extrapontina secundaria a fluctuaciones en la glucemia. <i>Neurología</i> , 2016, 31, 345-347.	0.3	6
120	Validación de la versión española del Mini-Addenbrooke's Cognitive Examination para el cribado de demencias. <i>Neurología</i> , 2016, 31, 646-648.	0.3	21
121	Validation of the Lille's Apathy Rating Scale in Very Mild to Moderate Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 517-527.	0.6	15
122	Análisis de las interconsultas al neurólogo de guardia por cefaleas en un servicio de urgencias. <i>Neurología</i> , 2016, 31, 577.	0.3	3
123	Estudio piloto de un nuevo método de estimulación aritmética empleando el tamborcillo en ancianos sanos y con trastorno cognitivo. <i>Neurología</i> , 2016, 31, 326-331.	0.3	6
124	Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study. <i>BMC Neurology</i> , 2015, 15, 243.	0.8	58
125	Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study. <i>Scientific World Journal</i> , The, 2015, 2015, 1-8.	0.8	28
126	A case of acute spinal intradural hematoma due to spinal anesthesia. <i>Journal of Acute Disease</i> , 2015, 4, 341-343.	0.0	6



#	ARTICLE	IF	CITATIONS
127	Validación de la versión española del test Addenbrooke's Cognitive Examination III para el diagnóstico de demencia. <i>Neurología</i> , 2015, 30, 545-551.	0.3	57
128	Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 916-927.	3.3	35
129	Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. <i>Journal of Neurology</i> , 2015, 262, 1463-1472.	1.8	39
130	Topography of primitive reflexes in dementia: an 18 fluorodeoxyglucose positron emission tomography study. <i>European Journal of Neurology</i> , 2015, 22, 1201-1207.	1.7	7
131	Clinical course of primary progressive aphasia: clinical and FDG-PET patterns. <i>Journal of Neurology</i> , 2015, 262, 570-577.	1.8	41
132	Demencia frontotemporal variante conductual: biomarcadores, una aproximación a la enfermedad. <i>Neurología</i> , 2015, 30, 50-61.	0.3	14
133	Afasia progresiva logopéunica asociada a enfermedad de Parkinson idiopática. <i>Neurología</i> , 2015, 30, 521-524.	0.3	1
134	Estudio de la asistencia neurológica ambulatoria en la Comunidad de Madrid: impacto del modelo de libre elección de hospital. <i>Neurología</i> , 2015, 30, 479-487.	0.3	8
135	Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study. <i>Scientific World Journal, The</i> , 2014, 2014, 1-7.	0.8	9
136	Validation of a Spanish Version of the Lille Apathy Rating Scale for Parkinson's Disease. <i>Scientific World Journal, The</i> , 2014, 2014, 1-7.	0.8	18
137	Stroke etiology determines effectiveness of retrievable stents: Table 1. <i>Journal of NeuroInterventional Surgery</i> , 2014, 6, e11-e11.	2.0	40
138	Primary progressive aphasia with occipital impairment. <i>Journal of the Neurological Sciences</i> , 2014, 347, 387-388.	0.3	3
139	Mechanical endovascular treatment of acute stroke due to cardiac myxoma. <i>Journal of NeuroInterventional Surgery</i> , 2014, 6, e1-e1.	2.0	35
140	Evaluation of the New Consensus Criteria for the Diagnosis of Primary Progressive Aphasia Using Fluorodeoxyglucose Positron Emission Tomography. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 147-152.	0.7	31
141	Cerebral venocclusive disease due to CNS T cell lymphoma. <i>Neurological Sciences</i> , 2014, 35, 947-949.	0.9	0
142	Oclusión arterial de gran vaso diagnosticada por angiografía por tomografía computarizada en el ictus isquémico agudo: frecuencia, factores predictores y seguridad. <i>Neurología</i> , 2014, 29, 261-266.	0.3	7
143	Suboptimal interventional conditions for the occlusion of ruptured intracranial aneurysms do not increase periprocedural complications and poor clinical outcomes. <i>Acta Neurochirurgica</i> , 2014, 156, 1267-1272.	0.9	0
144	Hiperintensidad pulvinar en T1: ¿un signo patognomónico de enfermedad de Fabry?. <i>Neurología</i> , 2014, 29, 442-443.	0.3	2

#	ARTICLE	IF	CITATIONS
145	Tratamiento endovascular del ictus isquémico agudo: en busca de la evidencia. <i>Neurología</i> , 2014, 29, 65-67.	0.3	1
146	Demencia frontotemporal variante conductual: aproximación clínica y terapéutica. <i>Neurología</i> , 2014, 29, 464-472.	0.3	16
147	Primary progressive aphasia: From syndrome to disease. <i>Neurología (English Edition)</i> , 2013, 28, 366-374.	0.2	20
148	¿Qué ocurre con los artículos médicos remitidos en español que no son aceptados para publicación?. <i>Neurología</i> , 2013, 28, 205-211.	0.3	4
149	What happens to medical articles submitted in Spanish that are not accepted for publication?. <i>Neurología (English Edition)</i> , 2013, 28, 205-211.	0.2	2
150	Afasia progresiva primaria: del síndrome a la enfermedad. <i>Neurología</i> , 2013, 28, 366-374.	0.3	30
151	Estenosis crónica de arteria basilar asociada a inestabilidad clínica: propuesta de una nueva indicación de tratamiento endovascular agudo. <i>Neurología</i> , 2013, 28, 321-322.	0.3	1
152	Endovascular Treatment of Distal Internal Carotid Artery Occlusions with Retrieable Stents. <i>European Neurology</i> , 2013, 70, 159-164.	0.6	5
153	Epicrania Fugax: 19 Cases of an Emerging Headache. <i>Headache</i> , 2013, 53, 764-774.	1.8	30
154	Peroneal palsy after bariatric surgery; is nerve decompression always necessary?. <i>Nutricion Hospitalaria</i> , 2013, 28, 1330-2.	0.2	8
155	Early Endovascular Treatment of Subarachnoid Hemorrhage. <i>Interventional Neurology</i> , 2012, 1, 56-64.	1.8	10
156	El acceso arterial humeral: una vía alternativa al acceso femoral en el tratamiento endovascular del ictus agudo. <i>Neurología</i> , 2012, 27, 448-449.	0.3	2
157	Humeral arterial access: An alternative route to the femoral artery in the endovascular treatment of acute stroke. <i>Neurología (English Edition)</i> , 2012, 27, 448-449.	0.2	1
158	Sulcal hyperintensity on FLAIR-MRI in a case of idiopathic intracranial hypertension. <i>Neurología (English Edition)</i> , 2012, 27, 313.	0.2	0
159	Recurrent reversible posterior encephalopathy syndrome with a response to nimodipine. <i>Neurología (English Edition)</i> , 2012, 27, 378-380.	0.2	1
160	Genital sensory aura in migraine. <i>Revista De Neurologia</i> , 2012, 55, 445-7.	7.6	0
161	Partial adrenocorticotropin hormone deficiency associated with multiple sclerosis. <i>Endocrinología Y Nutrición (English Edition)</i> , 2011, 58, 201-204.	0.5	1
162	Wallenberg's syndrome and symptomatic trigeminal neuralgia. <i>Journal of Headache and Pain</i> , 2011, 12, 377-380.	2.5	22

#	ARTICLE	IF	CITATIONS
163	Dementia, Stroke and Parkinson's Disease in Spanish Populations: A Review of Door-to-Door Prevalence Surveys. <i>Neuroepidemiology</i> , 2005, 24, 179-188.	1.1	38
164	Cognitive dysfunction in patients with primary adrenal insufficiency: A systematic review. <i>Applied Neuropsychology Adult</i> , 0, , 1-12.	0.7	2